833 abstracts found.



Results filter



Polygenic risk prediction: The clinical significance

Year:

Session type:

Paul Pharoah
University of Cambridge, UK



Unexplained familial breast cancer risk – how can we find the missing genes?

Year:

Session type:

Julian Peto
London School of Hygiene and Tropical Medicine, UK



Interrogating regulatory networks to elucidate drivers of tumourigenesis, progression, and drug sensitivity

Year:

Session type:

Andrea Califano
Columbia University, New York, USA



Recent insights into the tempo and mode of somatic evolution

Year:

Session type:

Carlo Maley
The University of California, San Francisco, USA



Evolutionary complexity in childhood acute lymphoblastic leukaemia

Year:

Session type:

Mel Greaves
The Institute of Cancer Research, London, UK



Evolution of cancer genomes

Year:

Session type:

Peter Campbell
Wellcome Trust Sanger Institute, Cambridge, UK



Improvements in palliative and supportive care: recent advances

Year:

Session type:

Irene Higginson
Cicely Saunders Institute, King’s College London, UK



Advances, challenges and opportunities in symptom management in older patients with cancer

Year:

Session type:

Deborah Dudgeon
Queen's University, Ontario, Canada



Recent advances in breast, cervix and oral cancer early detection and prevention in low and middle income countries

Year:

Session type:

Rengaswamy Sankaranarayanan
International Agency for Research on Cancer, World Health Organization, Lyon, France



Recent advances in developing a national end of life care register

Year:

Session type:

Carl Johan Fürst
Karolinska Institutet, Stockholm, Sweden



Cancer Control for India and Developing World

Year:

Session type:

Rajendra Badwe
Tata Memorial Centre, Mumbai, India



Recent advances in the detection and management of psychological distress and depression in cancer and palliative care

Year:

Session type:

Mari Lloyd-Williams
University of Liverpool, UK



Oncology drug development in 2012 – Challenges and opportunities of stratified patient populations

Year:

Session type:

Susan Galbraith
AstraZeneca, Macclesfield, UK



Lung cancer – state of the art and science

Year:

Session type:

Fergus Macbeth
Wales Cancer Trials Unit, Cardiff, UK



Translating pre-clinical hypotheses into the clinic – a tale of two kinases

Year:

Session type:

Nigel Brooks
AstraZeneca, Macclesfield, UK



The application of translational science in non-small cell lung cancer (NSCLC):  Successes, failures and pitfalls 

Year:

Session type:

Frances Shepherd
University of Toronto and Princess Margaret Hospital, Ontario, Canada



Developing novel anti-cancer therapies: Promises and challenges

Year:

Session type:

Jeff Evans
The Beatson Institute for Cancer Research, University of Glasgow & NHS Greater Glasgow and Clyde, Glasgow, UK



Lung Stereotactic Ablative Radiotherapy (SABR): The state of the art

Year:

Session type:

Kevin Franks
St James's Institute of Oncology, Leeds, UK



Delivering on the promise of personalised medicine.

Year:

Session type:

Gordon Mills
The University of Texas MD Anderson Cancer Center, USA



Radical radiotherapy for locally advanced NSCLC – Current research and controversies

Year:

Session type:

Corinne Faivre-Finn
The Christie NHS Foundation Trust, Manchester, UK



Targeting cancer cells and promoting the immune effectors: From models to the clinic

Year:

Session type:

Adrian Hayday
King's College London, UK



Tumour- environment interactions

Year:

Session type:

Margaret Frame
Edinburgh Cancer Research Centre, UK



Live imaging of the earliest inflammatory response to transformed cells within tissues – studies in zebrafish

Year:

Session type:

Paul Martin
University of Bristol, UK



Tumour-stroma interactions in breast cancer metastasis

Year:

Session type:

Clare Isacke
The Institute of Cancer Research, London, UK



Peptide antigen characterization for clinical immunotherapy studies

Year:

Session type:

Hans-Georg Rammensee
University of Tübingen, Germany



Prognostic, predictive and therapeutic potential of PDGFR-positive cancer-associated fibroblasts

Year:

Session type:

Arne Östman
Karolinska Institutet, Stockholm, Sweden



PD-1 and LAG-3 in Cancer Immunotherapy

Year:

Session type:

Charles Drake
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA



Intravital microscopy of tumour cells and their microenvironment through imaging windows

Year:

Session type:

Jacco van Rheenen
Hubrecht Institute, Utrecht, The Netherlands



Understanding cancer as a microevolutionary process

Year:

Session type:

Gerard Evans
University of Cambridge, UK



Where next with genome-wide association studies?

Year:

Session type:

Bruce Ponder
Cancer Research UK Cambridge Research Institute, UK

RASSF1A loss deregulates hippo pathway signalling in tumourigenesis.

Year:

Session type:

Angelos Papaspyropoulos1, Louise van der Weyden1, George Poulogiannis1, David Adams1, Eric O'Neill1
1University of Oxford, Oxford, UK

Identification of 14-3-3 as a Novel Regulator of the Wnt/β-Catenin Signaling Pathway

Year:

Session type:

Shiri Dovrat1, Alona Zilberberg1, Rina Rosin-Arbesfeld1
1Tel Aviv University, Tel-Aviv, Israel

Phenotypic heterogeneity in small cell lung cancer cells.

Year:

Session type:

Suzanne Meredith1, Jennifer Bryant1,3, Muhammad Babur3, Kaye Williams3, Anne White1,2
1Faculty of Life Sciences, University of Manchester, Manchester, UK, 2Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK, 3Pharmacy and Pharmceutical Sciences, University of Manchester, Manchester, UK



Cancer in low and middle income countries – an increasing threat to development

Year:

Session type:

Ian Magrath
International Network for Cancer Treatment and Research (INCTR), Brussels, Belgium

Audit of cisplatin-topotecan use in palliative cervical cancer 2008-2011

Year:

Session type:

Kirsty MacLennan1, Mark Zahra1
1Edinburgh Cancer Centre, Edinburgh, UK



Descriptive epidemiology of cancer in developing countries and its importance to cancer control

Year:

Session type:

D. Maxwell Parkin
Clinical Trial Service Unit, University of Oxford & Cancer Registry Programme, International Network for Cancer Treatment and Research, Oxford, UK

Chronic increase in mast cell numbers in human skin after radiotherapy for breast cancer

Year:

Session type:

Charlotte Westbury1, Alex Freeman3, Leonid Nikitenko1, Ann Pearson2, Mohammed Rashid1, John Yarnold2, Susan Short1
1UCL Cancer Institute, University College London, London, UK, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, 3Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK

Initial experience of dynamic contrast enhance magnetic resonance imaging (DCE-MRI) to assess therapeutic response to neoadjuvant chemotherapy and radical radiotherapy in bladder preservation for muscle invasive bladder cancer (MIBC)

Year:

Session type:

Carmel Anandadas1, Thomas Westwood1, Richard Cowan1, Jeanette Lyons1, Suzanne Bonington1, Bernadette Carrington1, Ananya Choudhury1, Stephanie Donaldson1
1The Christie NHS Foundation Trust, Manchester, UK

CXCL12 predicts relapse in stage I Non-Seminomatous Germ Cell Tumours (NSGCT); results from the MRC TE08 and TE22 clinical trials.

Year:

Session type:

Duncan Gilbert1,2, Khin Thway2, Ian Chandler3, Reem Al-Saadi2, Sally Stenning4, Rhian Gabe4, Robert Huddart5,2, Janet Shipley2
1Brighton and Sussex Medical School, Brighton, Sussex, UK, 2The Institute of Cancer Research, Sutton, Surrey, UK, 3Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK, 4Medical Research Council, London, UK, 5Royal Marsden Hospitals NHS Foundation Trust, Sutton, Surrey, UK

Is tumour volume a predictive factor for survival in patients after accelerated radiotherapy (CHART) or chemoradiotherapy for Non-Small-Cell Lung Cancer (NSCLC)?

Year:

Session type:

Waheeda Owadally1, Emma Gray1, Peter Jenkins1
1Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, Gloucestershire, UK

Validation of a novel diagnostic standard in HPV positive Oropharyngeal Squamous Cell Carcinoma

Year:

Session type:

Andrew Schache1, Triantafilos Liloglou1, Janet Risk1, Terence Jones1, Xiao-Jun Ma3, Hongwei Wang3, Son Bui3, Yuling Luo3, Philip Sloan2, Richard Shaw1, Max Robinson2
1University of Liverpool, Liverpool, UK, 2Newcastle University, Newcastle, UK, 3Advanced Cell Diagnostics, Hayward, CA, USA

Investigating the Functional Effects of Oncogenic FGFR2 Mutations in Endometrial Cancer

Year:

Session type:

Abbie Fearon1, Pedro Cutillas1, Richard Grose1
1Barts Cancer Institute, London, UK

HELQ helicase, a novel DNA crosslink repair protein with links to the RAD51 paralog BCDX2 complex

Year:

Session type:

Rafal Lolo1, Carrie Adelman1, Simon Boulton1
1London Research Institute, London, UK

PIK3CA Mutation is Strongly Associated with K-ras 12/13 Mutation in Stage II/III Colorectal Cancer

Year:

Session type:

Katie Southward1, Morag Taylor1, Phil Chambers1, Kelly Handley2, Laura Magill2, Claire Beaumont1, Susan Richman1, Matt Seymour3, David Kerr4, Richard Gray4, Phil Quirke1
1Leeds Institute of Molecular Medicine, Leeds, UK, 2Birmingham Clinical Trials Unit, Birmingham, UK, 3CRUK Cancer Centre, Leeds, UK, 4University of Oxford, Oxford, UK

The histone deacetylase inhibitor vorinostat (SAHA) down-regulates c-FLIP and sensitizes human non-small cell lung carcinoma cell lines to ionising radiation

Year:

Session type:

Kylie McLaughlin1, Izabela Stasik1, Kevin Prise1, Patrick Johnston1, Daniel Longley1
1Queen's University Belfast, Belfast, UK

Colorectal tumour microRNAs – novel biomarkers of tumour progression and treatment response?

Year:

Session type:

Edward Amankwatia1, Francis Carey1, Robert Steele1, Alastair Munro1, Roland Wolf1, Gillian Smith1
1University of Dundee, Dundee, UK

Propagation of epithelial polarity through mitosis

Year:

Session type:

Graham Bell1,2, Barry Thompson1
1Cancer Research UK, London, UK, 2University College London, London, UK

Toxicity of Loco-regional Treatment for Early Breast Cancer: What do our Patients have to say.

Year:

Session type:

Ee-Siang Choong1, Ada Keding1, Bindu Musunuru1, Jay Naik1, Sreedevi Kumar1
1St James's Institute of Oncology, Leeds, West Yorkshire, UK

A dose-response relationship for the incidence of radiation-related heart disease

Year:

Session type:

Carolyn Taylor1, Sarah Darby1, Marianne Ewertz2, Paul McGale1, Anna Bennet3, Ulla Blom-Goldman4, Dorthe Bronnum5, Candace Correa6, David Cutter1, Giovanna Gagliardi4, Bruna Gigante3, Maj-Britt Jensen7, Andrew Nisbet8, Kazem Rahimi1, Per Hall3
1Oxford University, Oxford, UK, 2Odense University Hospital, Odense, Denmark, 3Karolinska Institutet, Stockholm, Sweden, 4Karolinska University Hospital, Stockholm, Sweden, 5Aalborg Hospital, Aarlborg, Denmark, 6H Lee Moffitt Cancer Centre, Florida, USA, 7Danish Breast Cancer Cooperative Group, Copenhagan, Denmark, 8Royal Surrey County Hospital and Surrey University, Surrey, UK

Revising the radiobiological model of chemoradiation in head and neck cancer

Year:

Session type:

Sara Meade1, Paul Sanghera1, Christopher McConkey2, Jack Fowler3, John Glaholm1, Andrew Hartley1, George Fountzilas4
1Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, UK, 2Clinical Trials Unit, University of Warwick, Warwick, UK, 3Department of Human Oncology and Medical Physics, University of Wisconsin, Wisconsin, USA, 4AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece